ACQUISITIONS (Details) $ in Thousands			3 Months Ended		6 Months Ended
	Nov. 17, 2015 USD ($) patent	Apr. 02, 2015 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)	Apr. 30, 2016 USD ($)
Purchase price consideration
Research and development expenses			$ 5,614	$ 7,116	$ 10,698	$ 13,065
Amortization expense			25,735	27,037	51,470	54,074
Pro forma financial information (unaudited)
Net revenues			$ 100,457	$ 116,682	$ 190,904	$ 221,462
Endo
ACQUISITIONS
Number of patents infringed | patent	3
Senior Notes
Purchase price consideration
Aggregate principal amount of notes issued		$ 575,000					$ 375,000
Proceeds from the issuance of debt		562,000
Cebranopadol
Purchase price consideration
Cash Paid	$ 25,000
Research and development expenses	54,900
Cebranopadol | Endo
Purchase price consideration
Amount of one-time accounting adjustment	$ 29,900
NUCYNTA
Purchase price consideration
Cash Paid		1,050,000
Rebates payable by seller		(9,977)
Total Purchase Consideration		1,040,023
Fair values of tangible and identifiable intangible assets acquired and liabilities assumed
Intangible asset - acquired entity product rights		1,019,978
Inventories		11,590
Manufacturing Equipment		8,455
Estimated fair value of the assets acquired		$ 1,040,023
Estimated useful life of intangible asset		10 years
NUCYNTA | Senior Notes
Purchase price consideration
Proceeds from the issuance of debt		$ 550,000